Edward A Copelan
Overview
Explore the profile of Edward A Copelan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
1575
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hu B, Vaidya R, Ahmed F, Ehsan H, Moyo T, Jacobs R, et al.
Transplant Cell Ther
. 2024 Sep;
30(11):1082.e1-1082.e10.
PMID: 39270935
The implementation of chimeric antigen receptor T (CAR T) therapy in the real-world setting is hindered by logistical and financial barriers, impacting timely access to this life-saving treatment. Clinical trials...
2.
Hamilton B, Rybicki L, Li H, Lucas T, Corrigan D, Kalaycio M, et al.
Blood Adv
. 2023 Jun;
7(16):4505-4513.
PMID: 37352262
Tacrolimus (Tac)/methotrexate (MTX) is standard graft-versus-host disease (GVHD) prophylaxis; however, is associated with several toxicities. Tac, reduced-dose MTX (mini-MTX), and mycophenolate mofetil (MMF) have been used but never compared with...
3.
Shahid Z, Patrick A, Wallander M, Donahue E, Trufan S, Tan A, et al.
Vaccine X
. 2023 Apr;
14:100289.
PMID: 37020982
Purpose: Cancer patients are at high risk of developing severe illness from SARS-CoV-2 infection, but risk is lowered with receipt of COVID-19 vaccine. COVID-19 vaccination uptake among previously infected cancer...
4.
Boyiadzis M, Zhang M, Chen K, Abdel-Azim H, Abid M, Aljurf M, et al.
Leukemia
. 2023 Mar;
37(5):1173.
PMID: 36949156
No abstract available.
5.
Boyiadzis M, Zhang M, Chen K, Abdel-Azim H, Abid M, Aljurf M, et al.
Leukemia
. 2022 Oct;
37(5):1006-1017.
PMID: 36310182
We investigated the impact of the number of induction/consolidation cycles on outcomes of 3113 adult AML patients who received allogeneic hematopoietic cell transplantation (allo-HCT) between 2008 and 2019. Patients received...
6.
Chojecki A, Arnall J, Boselli D, Patel R, Chiad Z, DiSogra K, et al.
Leuk Res
. 2022 Jun;
119:106904.
PMID: 35753088
No abstract available.
7.
Knight T, Aguiar M, Robinson M, Morse A, Chen T, Bose R, et al.
JCO Oncol Pract
. 2022 Jun;
18(9):e1494-e1504.
PMID: 35709421
Purpose: Patients with hematologic malignancies are extremely vulnerable to financial toxicity (FT) because of the high costs of treatment and health care utilization. This pilot study identified patients at high...
8.
Chojecki A, DiSogra K, Arnall J, Cowgill N, Soni A, Packman C, et al.
Leuk Lymphoma
. 2022 Feb;
63(6):1515-1517.
PMID: 35105270
No abstract available.
9.
Hu B, Boselli D, Pye L, Chen T, Bose R, Symanowski J, et al.
Cancer
. 2021 Jul;
127(21):3991-3997.
PMID: 34289094
Background: Aggressive large B-cell lymphomas (LBCLs) are curable, but previous studies have shown inferior outcomes in minorities. Nurse navigation programs can improve patient outcomes by providing patient support. This study...
10.
Sanikommu S, Reese E, He J, Lee C, Ai J, Butler C, et al.
J Clin Apher
. 2021 Mar;
36(4):553-562.
PMID: 33710672
Administration of plerixafor with granulocyte-colony stimulating factor (G-CSF) mobilizes CD34+ cells much more effectively than G-CSF alone, but cost generally limits plerixafor use to patients at high risk of insufficient...